PharmacologyTier 1Medical Sciences concept

Statin-associated myopathy - spectrum and risk (myalgia, myositis, rhabdomyolysis)

Core concept

Statin myotoxicity is a spectrum, and the discriminator is what happens after the statin stops

Entity	CK	Weakness	Course off statin
Myalgia (commonest, 5-10%)	Normal	No	Resolves in weeks
Myopathy/myositis	inc (>ULN)	Mild	Resolves
Rhabdomyolysis	>10x ULN + myoglobinuria, AKI	Yes	Resolves
Immune-mediated necrotising myopathy (IMNM)	Very high, often >10x	Proximal, progressive	PERSISTS or PROGRESSES - the diagnostic clue

IMNM - anti-HMGCR antibodies; statin upregulates HMG-CoA reductase, which becomes the autoantigen
- Biopsy: myofibre necrosis and regeneration with LITTLE OR NO inflammatory infiltrate - unlike polymyositis
- Requires immunosuppression (steroids, MTX, IVIg), not just statin cessation
- Rare (~2-3 per 100,000 statin users) but the one that must not be missed
Proposed mechanism of common myopathy: dec mevalonate pathway -> dec coenzyme Q10 and dec prenylated proteins, mitochondrial dysfunction; nocebo effect contributes substantially to reported myalgia

Risk factors
- High dose and high systemic exposure; simvastatin 80 mg is no longer recommended
- Drug interactions raising statin levels - CYP3A4 inhibitors for simvastatin, atorvastatin, lovastatin; gemfibrozil (glucuronidation, all statins); ciclosporin, macrolides, azoles, protease inhibitors, verapamil/diltiazem, amiodarone, grapefruit
- Pravastatin, rosuvastatin, pitavastatin and fluvastatin are NOT CYP3A4-dependent - the substitution when an interaction cannot be avoided
- SLCO1B1 polymorphism (dec hepatic OATP1B1 uptake -> inc systemic exposure) - strongest for simvastatin
- Untreated hypothyroidism, vitamin D deficiency, older age, small body size, female, renal impairment, excess alcohol, vigorous exercise, Asian ancestry (rosuvastatin dosing)
Do not check CK routinely - check baseline CK only in high-risk patients, then check when symptoms occur
Statin-associated muscle symptoms are usually reproducible on rechallenge in <50% - blinded n-of-1 rechallenge (SAMSON, StatinWISE) confirms nocebo in most

Approach to muscle symptoms on a statin
- Mild symptoms, CK <4x ULN -> continue or dose-reduce, review interacting drugs, check TSH and vitamin D
- CK >10x ULN, or any weakness -> stop the statin, check renal function and urine myoglobin
- Recheck at 4-6 weeks off statin: CK and symptoms should normalise
- If CK stays high or weakness progresses -> anti-HMGCR antibodies, EMG, muscle biopsy - think IMNM
Rechallenge strategy: a different statin, lower dose, or alternate-day rosuvastatin/atorvastatin - most patients tolerate a statin eventually
- If truly intolerant: ezetimibe, then PCSK9 inhibitor, bempedoic acid (bempedoic acid is a prodrug activated only in liver, not muscle)
Withhold the statin for the duration of a clarithromycin or erythromycin course - a simple, exam-favoured action
Statin benefit is large and the muscle risk small - do not abandon lipid lowering because of myalgia

3 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.